

Vaccines Insights from Ongoing Trials

John Nemunaitis, MD Executive Medical Director Mary Crowley Cancer Research Centers Dallas, Texas

Results of Non-Gene-Based Vaccines in IIIB/IV NSCLC

Vaccine	Stage	# Pts	Median Survival	Reference
SRL172	IIIB/IV	210	7.3 months	O'Brien et al; 2004
CIMAvax EGF	III, IV	80	11.7 months (GAR*) vs. 3.6 months (PAR*)	Neninger, V. et al; 2008
CIMAvax EGF	IIIB, IV	43	Low dose: 6.43 months; High does: 8.4 months	Ramos, T.C. et al; 2006
Telomerase peptide	IIIB, IV, (I,III A)	26	8.5 months (36% 1yr)	Brunsvig, P.F. et al; 2006
BLP25 ^x	IIIB	88	17 months	Butts, C. et al; 2005
BLP25 ^x	IIIB/IV	171	3 year OS 31% for BLP25 / 17% for BSC (p=0.035)	Butts, C. et al; 2011
EP2101	IIIB/IV	135	17 months	Barve, M.; 2008
1E10	IIIB/IV	71	9.9 months	Alfonso et al.; 2007
1E10	IIIB/IV	20	10.6 months	Hernandez et al.; 2008
CEA pulsed DC's	IIIB/IV	14	22 months (64% 1 yr)	Zhang et al; 2011
Talactoferrin	IIIB/IV	110	RR° 47% (+Cb/Tx) vs. 29% (+Cb/Tx); p=0.05	Digumarti, R. et al. 2011
Ipilimumab	IIIB/IV	204	PFS 5.7 months (+Cb/Tx) vs. 4.6 (+Cb/Tx); p=0.05	Lynch, T. et al; 2012

* GAR = Good Antibody Response

°RR=Response Rate


* PAR = Poor Antibody Response

 $^{\rm x}$ Phase III trial involving 1,500 patients negative overall

Results of Gene-Based Vaccines in IIIB/IV NSCLC

Vaccine	Stage	# Pts	Median Survival	Reference
Allogenic Ad B 7.1	IIIB/IV	19	18 months (52% 1yr)	Raez, L.E. et al; 2004
GMCSF gene vaccine	IV	35	Not done	Salgia, R. et al; 2003
GMCSF gene vaccine	IIIB/IV	33	12 months (44% 1yr)	Nemunaitis, J. et al; 2004
GMCSF gene vaccine - bystander	IIIB/IV	49	7 months (31% 1 yr)	Nemunaitis, J. et al; 2006
Galactosyltransferase	IV	7	Not done	Morris, J.C. et al; 2005
Lucanix	IIIB/IV	61	14.4 months (56% 1 yr)	Nemunaitis, J. et al; 2007
Lucanix	IIIB/IV	21	15.5 months (72% 1 yr)	Nemunaitis, J. et al; 2008
TG4010	IIIB/IV	65	14.9 months (60% 1 yr)	Ramlau, R. et al.; 2008
TG4010	IIIB/IV	48	17.1 months	Quoix E et al; 2011

Adaptive Cancer Immune Mechanism



Confidential

Concept: "Triad" Immunotherapy

Immunotherapy that addresses the key elements necessary for an optimal immune attack against cancer

- 1) Patient Tumor Antigen (matrix)
- 2) Immune Activation
- 3) Inhibition of Afferent Immune Suppressors

Identify biorelevant surrogate of activity (correlating with survival)

BLP25

MUC1 antigen specific cancer immunotherapy advanced unresectable stage III NSCLS s/p so with concurrent or sequential XRT/chemo

START:

- 1,239 patient Phase III trial (2:1 randomization)
- Median OS 25.6 mo. BLP25
- AE's >10% include cough, dyspnea, fatigue, nausea, headache, arthralgia
- No treatment unique grade 3, 4 toxicity

Subset Analysis START Trial

- Concurrent XRT/chemo group (n=806)
- Median OS 30.8 mo. BLP25 vs. 20.6 mo.
 BLP25 p=0.016

What Did We Learn From BLP25

- Single antigen immunotherapy can be well-tolerated
- Suggestion of relevant activity survival advantage in a large sub population
- Unclear why concurrent vs. sequential XRT/chemo different
- No surrogate measure of activity

Targeted Immune Activation Tumor Responses to GMCSF Gene Vaccine

9/20/00 baseline






2/28/01 post





5/19/00 baseline

1/22/01 post*





3/10/00 baseline





8/2/00 post*





* Still alive/no recurrence

Nemunaitis J, et al. J Natl Ca Inst. 2004; 96(4):326-331.


Wednesday, June 05, 2013

Confidential

So What Did We Learn With GVAX

- Clinically relevant immune mediated activity can be observed (limited degree)
 - Multi-antigen autologous cells despite "tolerance" can also provide immunogenic stimulus
 - No significant toxic effect was observed
 - Beneficial results can be prolonged (>10 year)
- No surrogate measure of activity

Vector/Effector –T-VEC



Modes of Action

1.Oncolytic (tumor specific)


a.-ICP34.5 (decreased normal tissue virulence)

b.L->IE US11 (enhanced oncolytic cytotoxicity)

2.Immunogenic

a.-ICP47 (enhanced antigen presentation; increased levels class I MHC confirmed by FACS analysis)

• RECIST response was 26% (8CR, 5PR) and regression of local injected and distal (non injected) lesions were observed






Patient 603: Baseline (red \uparrow) and at 4 months.

Patient 1502 Axillary injection of T-VEC (red↓) metastatic (yellow↓) disease regression shown by PET 16 months later

Belagenpumatucel: Inhibition of Intrinsic **Tumor Immunosuppressors** (4 allogeneic NSCLC lines / TGFβ₂ AS transfection)




Confidential

Nemunaitis et al. JCO 2006 10; 24(29):4721-4730. Nemunaitis et al. CGT 2009; 16(8):620-624.

Belagenpumatucel: Phase III (STOP Trial) Results

- Phase III testing in front line NSCLC were negative.
 - Subset analysis by NovaRx suggestive of benefit




* Data from all clinical sites except one with significant compliance issues


So What Did We Learn With Belagenpumatucel?

- Phase II trials suggested evidence of clinical benefit in subsets of patients with ≥ 2nd line NSCLC
- Phase III trial suggests insufficient clinical response in front line NSCLC
 - □ But Why?
 - Allogeneic tumor antigens less efficient then autologous tumor antigen?
 - TGFβ₂ knockdown insufficient (TGFβ1 is dominant TGFβ cancer immunosuppressor)
 - Level of Knockdown insufficient (35-50%)?
 - Physiologic effects related to subset sensitivity/resistance
- No Surrogate measure of activity

TG4010 (Recombinant Vaccinia Virus/MUC1 Antigen IL2 Transgene) Early Safety Signal: Correlation with aNK Cells Level



TG4010 Overall Survival in Patients with Normal Level of Activated NK Cells in Advanced NSCL



What Did We Learn From TG4010?


- Subsets of patients may benefit from relevant tumor antigen education
- Immune function enhancement may contribute
 to clinical benefit
- Identification of predictor biorelevant measures of activity may be feasible
 - Level of Activated NK cell activity affects outcome: possible predictive marker

Could "Triad" Approach Provide a Greater Activity


- Patient/tumor-specific antigen education
- Enhanced afferent immune activation
- Blockade of intrinsic immune suppressors
 - Identify surrogate measure of biorelevant activity


Nemunaitis. Expert Review of Vaccines 2011; 10(6):713-715

Triad Vaccine Mechanism




Furin pro-protein convertase – immunomodulatory TGF $\beta_{1,}\beta_{2}$ (Gradalis, Inc., Dallas, TX)






FANG[™] Phase I Trial 6/8/09


- Vaccine constructed following autologous tissue harvest and electroporated transfer of bishRNA^{furin} GMCSF vector
- 2 dose levels (1x10⁷ / 2.5x10⁷ cells/inj)
- Monthly ID injection (maximum of 12 months)
- Two groups of patients: other options prior to FANG[™] vs. no options → FANG[™]
- ELISPOT for T cell activation at baseline and follow up timepoints



Survival of Treated Patients Since Treatment Start on FANG[™] Phase I Protocol[°]



Survival of Treated Patients Since Procurement on FANG[™] Phase I Protocol




Confidential

FANG Vaccine: Toxicity


Patient #018 Colon Adenocarcinoma



- No treatment related Grade 3, 4 toxic events
- Minor low grade events such as injection site irritation, fatigue observed



FANG Phase I Survival Relationship to Immune Response




Survival Based on Month 4 ELISPOT Response

Moved into Phase I Expansion Phase II Trial Program*

CL-PTL-101	Phase I Trial of FANG Expansion of NSCLC, Hepatocellular, Renal, Ewings, Thyroid
CL-PTL-105*	Randomized Phase II Trial of Adjuvant bi-shRNA ^{furin} and
	GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage IIIc Ovarian Cancer (Adjuvant)
CL-PTL-107	Randomized Phase II Trial of Post-operative Adjuvant
	Chemotherapy ± FANG [™] Autologous Tumor Cell Vaccine in
	Colorectal Carcinoma with Liver Metastases (Concurrent
	chemotherapy)
CL-PTL-114*	Phase II Trial of FANG [™] Autologous Tumor Cell Vaccine in
	Advanced Melanoma (Correlate Intratumoral/serologic
	immune markers)

* Secured orphan product designation in Stage III/IV melanoma and ovarian cancer

Successful Vaccine Construction Rate




*including 2 pre-clinical and 1 benign

Phase II Ovarian (III/IV)Trial Design

- 2:1 randomized trial
 - FANG vs. No FANG (n=60 treated/evaluable)
- 1x10⁷ cells/inj 2 month (max 12/minimum 4)
- Standard of care (debulking surgery \rightarrow 6 cycles carboplatin/taxol±IP) prior to FANG
- Crossover if PD (FANG/Avastin)

Disease-Free Survival Interval: Preliminary Analysis



Conclusion

- Evidence of increasing beneficial and safe immune modulatory activity is observed in advanced NSCLC to novel targeted immunotherapies
- Employment of "Triad" functions to vaccine effect should be considered (multi vaccines/single "triad" therapeutics)
- Surrogate biomarkers correlating response/survival to mechanism facilitate immunotherapy development